About the Center

The Diabetes and Endocrinology Center of Western New York is part of a comprehensive clinical care and education program sponsored by the State University of New York at Buffalo School of Medicine is lead by Paresh Dandona M.D., who has had an illustrious career in both American and English Medicine.

After contributing more than 400 publications for medical literature, Dr. Dandona continues to make research a high priority. The center currently has several studies in progress and more are in the process of being realized in the future.

Research Studies

The Diabetes and Endocrinology Center of WNY is actively recruiting patients for different research studies in the field of diabetes, obesity and endocrine diseases. Please visit our research page for a list of active research studies available.

Clinical Service

Our clinical unit offers the best care possible for Diabetes, which is considered to be the most expensive chronic disease in the United States, as well as for other endocrine pathologies. The center is due to see 16,000 patients this year, making it the biggest academic diabetic unit in New York state.

Director Paresh Dandona, MD

SUNY Distinguished Professor



Precision in Science, Just as in Nature


Community Functions

Our director, Dr. Dandona’s pioneering work in the diabetic center lead to his appointment as an advisor to Independent Health, Blue Cross, Blue Shield and to Community Blue in matters related to diabetes. We’ve authored algorithms in diabetic management, which we disseminated to primary care physicians so that care of diabetes can be improved and it’s complications prevented.

Various community programs have been set up by the Center for the city, which include: Public health surveys which screens for hypercholesterolemia, diabetes, hypothyroidism and hypertension starting in 1995 and then annually thereafter. Data from initial surveys have shown us for the first time that 2/3 of Buffalo’s population has hypercholesterolemia (high cholesterol) and that the prevalence of diabetes in the region is eight percent. So far 9500 Western New Yorkers have been surveyed. Every year we do our best to raise funds for this activity which amounts to $45,000-50,000. These screenings are done in association with the Erie County Health Dept.

A unique Diabetes Patients’ Forum which meets every two months, since October 1996, which aims to empower and educate diabetic patients and their families. This forum aims to educate patients and their families regarding their conditions and empower them to ask questions regarding the management of their disease.

Endocrinology Diary for 2013

May: 2013

American College of Endocrinology and American Association of Clinical Endocrinologists, Phoenix, AZ
This meeting was held in early May and one of the 10 chosen oral presentations was the one on the beneficial effects of testosterone in patients with hypogonadotropic hypogonadism. This led to a press release. Several abstracts based on clinical cases were presented by the fellows. These unique cases also raised a lot of interest.

Dr. Dandona participated in global consultants meeting related to the new anti-diabetic drug, TAK-875, from Takeda Pharmaceuticals in London, UK. This new class of drugs binds to a fatty acid receptor on the β-cell in the pancreatic islet and induces the release of insulin. The fall in HbA1c is just under 1% and there is no risk of hypoglycemia. Dr Prabhakar Viswanathan, Senior Medical Director in Takeda, is leading the program to develop this drug. Dr Viswanathan is an ex-fellow from our research program from UB. He is the third fellow trained by Dr Dandona to hold such a senior position in a major pharmaceutical company. Drs Davinder (Dave) Gill and Jaswinder (Jaz) Gill (Sanofi-Aventis) are the other two.

June: 2013

Department of Medicine Research Day
This day witnessed an outstanding performance by our division with the prizes for the best research and best case presentation being awarded to Manav Batra and Cherie Vaz.

Immunometabolism Symposium, Toronto
Dr Dandona attended this meeting and contributed to the discussions during this meeting in relation to our groups’ large body of work linking metabolic states and macronutrient intake to oxidative stress and inflammation.

ADA meeting:  Chicago IL

Abstracts on Research

  • Two major symposia where conducted highlighting research concepts which germinated in out unit.
    • Hypogonadotropic hypogonadism: Dr. Dhindsa and Dr. Chaudhuri made outstanding presentations, with an attending audience of 2500. Dr Chaudhuri was invited to chair this session. A pioneering discussion on the pathophysiological state of HH and the novel effects of testosterone were presented by Dr Dhindsa. Dr Chaudhuri concluded the discussion and presented the current rationale and modes of treatment of this condition.
    • The second symposium took the form of a debate on the use of insulin vs. Glucagon like Peptide 1 (GLP-1) receptor agonists. Dr. Dandona and Dr. Vivian Fonseca, the past president of the ADA and also a past fellow trained by Dr Dandona represented the two positions. The symposium was a success and had an attending audience of 2500.
  • During the course of the ADA meeting, Dr Dandona was invited to consultant board meetings of Sanofi-Aventis, Boehringer Ingelheim and Eisai Pharmaceuticals. The new product lines were discussed. There may be possibilities of novel hypotheses and protocols in relation to empagliflozin, lorcaserin and linagliptin.


Endocrine Society, San Francisco

 Abstracts Presented with oral presentation


  • Dr. Dandona participated in a symposium on GLP-1 receptor agonists, attended by 1000 doctors and CDEs.
  • Dr. Dhindsa Presented work on novel effects in testosterone in male patients with type 2 diabetes with Hypogonadotropic Hypogonadism men.
  • Husam Ghanim presented data on the anti-inflammatory effects of exenatide, on the Nrf-2/Keap-1 system and on its stimulatory effect on interleukin-1 receptor antagonist.
  • The work on testosterone replacement was recognized by the Endocrine Society as one of the 3 best abstracts in the area of diabetes and Dr Dandona was invited for a special presentation to the press. This brought back the memories of the Boston meeting in 2011 when our abstract on liraglutide in type 1 diabetes was adjudged as the best among diabetes related abstracts and again there was a press conference.

Our paper on effects of liraglutide in obese patients with type 1 diabetes is published online in Endocrine Practice.




The new batch of Fellows joined.
Dr Dandona was invited to be a member of the Special Programs Group of the Endocrine Society.
Our paper linking obesity with asthma through an increased expression of asthma related genes in obesity was published in the journal, OBESITY.


Webmaster contact: jshejna@hotmail.com

free web hit counter

Division of Endocrinology, Diabetes, and Metabolism,
State University of New York at Buffalo